In BC, specifically the expression of IGF-1R is at least 50% (Ekyalongo and Yee, 2017), much more compared to HER2+ positive BC, which represents 20–25% BC (Wang and Xu, 2019); besides, there is a broader potential group of patients that could be candidates for targeted therapy. This evidence concerns the gene IGF1R and breast cancer.